TUMOR MICROENVIRONMENT

肿瘤微环境

基本信息

项目摘要

The growth and spread of cancer involves not just the malignant cells themselves, but also other "host" cells in the tumor microenvironment. For example, angiogenesis provides oxygen and nutrients to the cancer cells, and also provides a mechanism by which cancer cells metastasize. Inflammatory and immune cells play important cooperating roles by generating a hospitable environment for both tumor growth and metastasis. And stromal cells such as fibroblasts are often also sources of growth factors that promote tumor growth, as well as the proteases that degrade and remodel the extracellular matrix, and thus change the adhesive properties of the cancer cells. The goals of the Tumor Microenvironment Program are to understand the molecular basis for the cell/cell and cell/matrix interactions, cell adhesions and cell migrations that take place during tumorigenesis, and to define how to limit tumorigenesis with chemical or biological inhibitors of cancer cells and the tumor microenvironment. The Tumor Microenvironment Program (TME) was formed in 2007 by merging the Cell Adhesion & Extracellular Matrix Program with the Glycobiology Program, to take advantage of and further promote the synergies already existing in the two programs. The Program consists of 16 interactive laboratories, with expertise in structural biology, carbohydrate chemistry, cryoelectron microscopy, computational analyses, signal transduction, integrin biology and animal models of tumor growth and metastasis. The research in the Program can be described in terms of three overiapplng themes: mechanisms and contributions of vascular and lymphoid components to tumor progression; the basic biology of metastasis (including the role of proteases); and the contribution of carbohydrate modifications to cancer invasion and progression. In addition, program members have an emerging interest in exploring the role of metabolism in cancer progression. In the last funding period, 3 new recruits were added to the Program, including the Program Leader, Dr. Sara Courtneidge. Members interact at a number of levels, including monthly faculty meetings, a recently established postdoc retreat, and through collaborative grants. Program funding is strong, with current total annual grant funding of $31.6MM ($18.3MM direct). Program Members currently lead or participate in 25 ROIs (14 from NCI), 6 P01s (4 from NCI), and 9 U54/U19 grants (1 from NCI). Our productivity is reflected in our 430 publications since last review, and by 81 Program publications in 2008, with 12% intra- and 13% inter-programmatic collaborations.
癌症的生长和扩散不仅涉及恶性细胞本身,还涉及其他“宿主”细胞。 在肿瘤微环境中。例如,血管生成为癌症提供氧气和营养物质。 细胞,也提供了癌细胞转移的机制。炎性和免疫细胞 发挥重要的合作作用,为肿瘤生长和 转移。成纤维细胞等间质细胞通常也是促进肿瘤的生长因子的来源。 生长,以及降解和重塑细胞外基质的蛋白酶,从而改变 癌细胞的粘附性。肿瘤微环境计划的目标是 了解细胞/细胞和细胞/基质相互作用、细胞黏附和细胞的分子基础 在肿瘤形成过程中发生的迁移,并定义如何使用化学或 癌细胞和肿瘤微环境的生物抑制物。 肿瘤微环境计划(TME)于2007年成立,将细胞黏附和 细胞外基质计划和糖生物学计划,以利用和进一步促进 这两个方案中已经存在协同效应。该计划由16个互动实验室组成,其中 擅长结构生物学、碳水化合物化学、低温电子显微镜、计算分析、 信号转导,整合素生物学和肿瘤生长和转移的动物模型。《科学与技术》中的研究 该计划可以用三个主要主题来描述:血管的机制和贡献 和淋巴成分对肿瘤进展的影响;转移的基本生物学(包括 以及碳水化合物修饰对癌症侵袭和进展的贡献。在……里面 此外,项目成员对探索新陈代谢在癌症中的作用产生了新的兴趣 进步。在上一个供资期间,该方案增加了3名新征聘人员,包括该方案 领队,莎拉·考特奈奇博士。成员在许多层面上进行互动,包括每月的教职员工会议、 最近建立了博士后休养所,并通过合作赠款。计划资金雄厚, 目前的年度赠款资金总额为3160万美元(直接拨款1830万美元)。计划成员目前领导或 参与25项ROI(14项来自NCI)、6项P01(4项来自NCI)和9项U54/U19资助(1项来自NCI)。我们的 自上次审查以来,我们的430份出版物和2008年的81份计划出版物反映了生产率, 12%的方案内协作和13%的方案间协作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SARA A COURTNEIDGE其他文献

SARA A COURTNEIDGE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SARA A COURTNEIDGE', 18)}}的其他基金

Validating and Characterizing a New Melanoma Therapeutic Target
验证和表征新的黑色素瘤治疗靶点
  • 批准号:
    9752264
  • 财政年份:
    2017
  • 资助金额:
    $ 12.01万
  • 项目类别:
Validating and Characterizing a New Melanoma Therapeutic Target
验证和表征新的黑色素瘤治疗靶点
  • 批准号:
    9532806
  • 财政年份:
    2017
  • 资助金额:
    $ 12.01万
  • 项目类别:
Src, p53 and estrogen receptor-positive breast cancer
Src、p53 和雌激素受体阳性乳腺癌
  • 批准号:
    8926363
  • 财政年份:
    2014
  • 资助金额:
    $ 12.01万
  • 项目类别:
Src, p53 and estrogen receptor-positive breast cancer
Src、p53 和雌激素受体阳性乳腺癌
  • 批准号:
    8610636
  • 财政年份:
    2014
  • 资助金额:
    $ 12.01万
  • 项目类别:
PROGRAM LEADERS
项目负责人
  • 批准号:
    8378375
  • 财政年份:
    2012
  • 资助金额:
    $ 12.01万
  • 项目类别:
Kinases as therapeutic targets for cancer progression
激酶作为癌症进展的治疗靶点
  • 批准号:
    8917353
  • 财政年份:
    2011
  • 资助金额:
    $ 12.01万
  • 项目类别:
Kinases as therapeutic targets for cancer progression
激酶作为癌症进展的治疗靶点
  • 批准号:
    8403646
  • 财政年份:
    2011
  • 资助金额:
    $ 12.01万
  • 项目类别:
Kinases as therapeutic targets for cancer progression
激酶作为癌症进展的治疗靶点
  • 批准号:
    8056016
  • 财政年份:
    2011
  • 资助金额:
    $ 12.01万
  • 项目类别:
Kinases as therapeutic targets for cancer progression
激酶作为癌症进展的治疗靶点
  • 批准号:
    8204723
  • 财政年份:
    2011
  • 资助金额:
    $ 12.01万
  • 项目类别:
Kinases as therapeutic targets for cancer progression
激酶作为癌症进展的治疗靶点
  • 批准号:
    8599753
  • 财政年份:
    2011
  • 资助金额:
    $ 12.01万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 12.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了